While a combined inhibition of CXCR4 and CXCR7 may be advantageous for cancer treatment by more completely inhibiting CXCL12 signaling, more highly specific inhibitors may significantly reduce the side effects linked to small molecule inhibitors. The gene discussed is CXCL12; the disease is cancer.